NO20022125L - Pyrrolderivater som inhibitorer for fosfodiesterase VII - Google Patents

Pyrrolderivater som inhibitorer for fosfodiesterase VII

Info

Publication number
NO20022125L
NO20022125L NO20022125A NO20022125A NO20022125L NO 20022125 L NO20022125 L NO 20022125L NO 20022125 A NO20022125 A NO 20022125A NO 20022125 A NO20022125 A NO 20022125A NO 20022125 L NO20022125 L NO 20022125L
Authority
NO
Norway
Prior art keywords
inhibitors
pyrrole derivatives
phosphodiesterase vii
hal
phosphodiesterase
Prior art date
Application number
NO20022125A
Other languages
English (en)
Other versions
NO20022125D0 (no
Inventor
Hans Michael Eggenweiler
Rochus Jonas
Michael Wolf
Michael Gassen
Thomas Welge
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20022125D0 publication Critical patent/NO20022125D0/no
Publication of NO20022125L publication Critical patent/NO20022125L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)

Abstract

Forbindelser med formel (1) hvor R1 og R2 uavhengig av hverandre betyr H, A, OA, SA eller Hal; R3 betyr H eller A; R4 betyr A eller NH2; R5 betyr H, NH2, NHA eller NA2; A betyr alkyl med 1-10 C-atomer, alkenyl, sykloalkyl eller alkylensykloalkyl; Hal betyr F, Cl, Br eller I; samt deres fysiologisk akseptable salter og/eller solvater, som fosfodiesterase Vll-inhibitorer.
NO20022125A 1999-11-04 2002-05-03 Pyrrolderivater som inhibitorer for fosfodiesterase VII NO20022125L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19953025A DE19953025A1 (de) 1999-11-04 1999-11-04 Pyrrolderivate als Phosphodiesterase VII-Hemmer
PCT/EP2000/010526 WO2001032618A1 (de) 1999-11-04 2000-10-25 Pyrrolderivate als phosphodiesterase vii-hemmer

Publications (2)

Publication Number Publication Date
NO20022125D0 NO20022125D0 (no) 2002-05-03
NO20022125L true NO20022125L (no) 2002-05-03

Family

ID=7927861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022125A NO20022125L (no) 1999-11-04 2002-05-03 Pyrrolderivater som inhibitorer for fosfodiesterase VII

Country Status (22)

Country Link
US (1) US6737436B1 (no)
EP (1) EP1230215B1 (no)
JP (1) JP2003513070A (no)
KR (1) KR20020063173A (no)
CN (1) CN1382122A (no)
AR (1) AR026351A1 (no)
AT (1) ATE339403T1 (no)
AU (1) AU782477B2 (no)
BR (1) BR0015334A (no)
CA (1) CA2389709C (no)
CZ (1) CZ20021440A3 (no)
DE (2) DE19953025A1 (no)
ES (1) ES2272331T3 (no)
HK (1) HK1049831A1 (no)
HU (1) HUP0203288A3 (no)
MX (1) MXPA02004440A (no)
NO (1) NO20022125L (no)
PL (1) PL355099A1 (no)
RU (1) RU2002113750A (no)
SK (1) SK5952002A3 (no)
WO (1) WO2001032618A1 (no)
ZA (1) ZA200204433B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946481B1 (en) * 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
CN1264843C (zh) 2001-12-13 2006-07-19 第一阿斯比奥制药株式会社 具有pde7抑制作用的吡唑并嘧啶酮衍生物
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
DE10226420A1 (de) * 2002-06-13 2004-01-15 Eucro European Contract Research Gmbh & Co Kg Verfahren zur Behandlung der Artherosklerose
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
RU2376309C2 (ru) 2004-07-01 2009-12-20 Асубио Фарма Ко., Лтд. Производное тиенопиразола, имеющее ингибирующую фосфодиэстеразу 7 (pde 7) активность
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2681650C (en) * 2007-03-27 2016-11-22 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
KR102640696B1 (ko) 2017-07-12 2024-02-27 다트 뉴로사이언스, 엘엘씨 Pde7 억제제로서 치환된 벤즈옥사졸 및 벤조푸란 화합물
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE154827C (no)
DD154827A1 (de) * 1980-11-28 1982-04-21 Karl Gewald Verfahren zur herstellung von azofarbstoffen aus substituierten 3-aminopyrrolen
PT946507E (pt) 1996-12-10 2004-02-27 Searle & Co Compostos de pirrolilo substituidos para o tratamento da inflamacao

Also Published As

Publication number Publication date
PL355099A1 (en) 2004-04-05
EP1230215B1 (de) 2006-09-13
SK5952002A3 (en) 2002-09-10
CZ20021440A3 (cs) 2002-07-17
CN1382122A (zh) 2002-11-27
BR0015334A (pt) 2002-07-09
EP1230215A1 (de) 2002-08-14
HK1049831A1 (zh) 2003-05-30
DE50013473D1 (de) 2006-10-26
ZA200204433B (en) 2003-09-03
AR026351A1 (es) 2003-02-05
JP2003513070A (ja) 2003-04-08
CA2389709C (en) 2009-02-10
NO20022125D0 (no) 2002-05-03
MXPA02004440A (es) 2004-09-10
ES2272331T3 (es) 2007-05-01
DE19953025A1 (de) 2001-05-10
HUP0203288A2 (hu) 2003-01-28
HUP0203288A3 (en) 2003-12-29
RU2002113750A (ru) 2004-01-10
US6737436B1 (en) 2004-05-18
ATE339403T1 (de) 2006-10-15
AU782477B2 (en) 2005-08-04
AU1387301A (en) 2001-05-14
KR20020063173A (ko) 2002-08-01
CA2389709A1 (en) 2001-05-10
WO2001032618A1 (de) 2001-05-10

Similar Documents

Publication Publication Date Title
NO20022125L (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
HUP0001054A2 (hu) IV-típusú foszfodiészteráz inhibitor 1-aril-1,8-naftiridin-4-on-származékok
DK1389617T3 (da) Heterocyclisk forbindelse og antitumormiddel indeholdende denne som den aktive bestanddel
DK1054874T3 (da) Substituerede aminophenylisoxazolinderivater, der er anvendelige som antimokrobielle midler
YU57603A (sh) Inhibitori fosfodiesteraze 4
AP2001002046A0 (en) Heterocyclic compounds as inhibitors of rotamase enzymes.
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
PT918776E (pt) Sintese total de acilfulvenos antitumorais
HK1039316A1 (zh) 具有一氧化氮合成酶抑制作用的苯胺衍生物
MX9800718A (es) Derivados de 2-(4-substituidos)-bencilamino-2-metil- propanamida.
NO20022232L (no) Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
WO2002028844A1 (fr) Dérivés thiazole ou oxazole
AU2001269540A1 (en) Serotonin reuptake inhibitors
MY117159A (en) Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation.
EP1357124A4 (en) HETEROCYCLIC COMPOUNDS AND COMPOSITIONS IMPROVING CEREBRAL FUNCTIONS CONTAINING THESE AS ACTIVE INGREDIENTS
DK1303514T3 (da) Fremgangsmåde til fremstilling af azacycloalkanoylaminothiazoler
DK0812835T3 (da) Optisk aktive thiazolidinonderivater
EP0407621A4 (en) Benzothiazole derivatives
NO995289D0 (no) Benzimidazol-derivater
ES2190781T3 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
BG106048A (en) 6-[[(aryl and heteroaryl)oxy]methyl]naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof
FI902775A0 (fi) Aryloxi-, aryltio-, heteroaryloxi-, heteroaryltio-alkylenderivat av aminer.
ES2206296T3 (es) Derivados de tienopiranocarboxamida.
PL321309A1 (en) Novel bis-imide compounds, method of obtaining them and pharmaceutic compositions containing such compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application